Developer docs
API playgroundTry for free, no card

Search company profiles

Medley

Full company profile

uuid000mycy

Namestring
Medley
Legal namestring
MEDLEY FARMACÊUTICA LTDA.
Websiteurl
medley.com.br
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Medley Farmacêutica Ltda. is a Brazilian generic pharmaceutical manufacturer founded in 1996 and headquartered in Campinas, São Paulo. It produces tablets, capsules, liquids, ointments, creams, and suspensions across more than eight therapeutic categories — anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants/anti-allergic, gynecological/urological, and anti-inflammatory/analgesic/antipyretic — and holds an estimated 8% share of Brazil's generics segment, where generics account for roughly 40% of the country's pharmaceutical market. Manufacturing is concentrated at a single ~1,800-employee Campinas production site on R. Macedo Costa, 55; the company operates under ANVISA regulatory oversight and maintains LGPD-compliant data practices.

The company's business model is sales-led distribution of generic medicines through Brazilian pharmacy retail chains, independent drugstores, and online pharmacy partners such as consultaremedios.com.br, targeting both end consumers and pharmacy/distributor buyers. Revenue derives from one-time unit sales across a portfolio of 100+ generic SKUs, with no disclosed subscription or licensing model. Medley complements its core generics franchise with branded OTC extensions (Termomed Ibup, Medalgesico, Medmulher), a nutraceutical product (Biscal D, launched in India in December 2025), and a digital mental-health engagement layer via Cássia on WhatsApp.

From 2009 until March 2026, Medley operated as a wholly-owned subsidiary of Sanofi. In March 2026, Sanofi signed a definitive agreement to sell 100% of Medley to Brazilian pharmaceutical group EMS for approximately BRL 3.2–3.6 billion (~US$660–670 million), at roughly 16x EBITDA, pending approval from Brazil's antitrust authority CADE. The deal would consolidate Medley with EMS's 23% generics share into a combined 31% market-leading position, with competing bids reported from Sun Pharma, Hypera Pharma, Biolab, and Aché.

Short descriptiontext

Medley Farmacêutica is a Brazilian generic pharmaceutical manufacturer founded in 1996, producing tablets, capsules, liquids, and creams across 8+ therapeutic categories from its ~1,800-employee Campinas facility and serving Brazilian pharmacy retailers and patients with an 8% generics market share.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCampinas, Brazil
HQ citystring
Campinas
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, generic medications, OTC medicines, pharmaceutical manufacturing, generic drugs Brazil
Industry2 codes
1Generic Hospital & Institutional Products
CodeHLAIABALPrimaryYes
2Women’s Health (OTC Gynecologic)
CodeHLAIADAJPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic pharmaceutical products
TypeOne Time License
Description

Medley generates revenue through the manufacture and sale of generic pharmaceutical products across multiple therapeutic categories including anti-infectives, cardiovascular, central nervous system, dermatologicals, gastrointestinal, and other medications. The company operates in Brazil's generics segment where generic medicines account for approximately 40% of the pharmaceutical market.

marketscreener.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medley manufactures and supplies a comprehensive portfolio of generic pharmaceutical products in multiple dosage forms (tablets, capsules, liquids, ointments, creams, and suspensions) spanning therapeutic categories including anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants, and gynecological/urological medications. The company also markets over-the-counter (OTC) brands such as Termomed Ibup, Medalgesico, and Medmulher, and operates the Cássia WhatsApp-based virtual mental health assistant.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Brazil's generics market represents approximately 40% of the total pharmaceutical market
Product overview1 text field

Medley is a leading Brazilian pharmaceutical company specializing in generic medications. The company produces a comprehensive portfolio of generic drugs including tablets, capsules, liquids, ointments, creams, and suspensions across multiple therapeutic categories: anti-infectives, anti-inflammatory/analgesic/antipyretic, cardiovascular, dermatological, gastrointestinal, expectorants/anti-allergic, gynecological/urological, and central nervous system medications. Medley also offers over-the-counter products including Termomed Ibup (fever relief), Medalgesico (pain and fever relief), and Medmulher (women's health). Additionally, the company offers digital health services through Cássia, a WhatsApp-based virtual mental health assistant. Founded in 1996 and acquired by Sanofi in 2009, Medley was subsequently acquired by EMS Group in 2026 for approximately BRL 3.2-3.6 billion (~$660-670 million).

Product and service6 records
1Generic Medications Portfolio
CategoryPrescription generic pharmaceuticals
Description

Comprehensive portfolio of generic medications including tablets, capsules, liquids, ointments, creams, and suspensions spanning therapeutic categories such as anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants, and gynecological/urological medications for the Brazilian population.

2Termomed Ibup
CategoryOTC pharmaceutical
Description

Over-the-counter analgesic product providing fever relief for the whole family.

3Medalgesico
CategoryOTC pharmaceutical
Description

Over-the-counter pain relief and fever medication for the whole family.

4Medmulher
CategoryOTC pharmaceutical
Description

Over-the-counter medication line focused on women's health.

5Biscal D
CategoryNutraceutical
Description

A fortified biscuit product containing Calcium and Vitamin D3 aimed at addressing nutritional deficiencies in pregnant women, lactating mothers, and postmenopausal women, launched in the Indian nutraceutical market.

6Cássia
CategoryDigital health service
Description

WhatsApp-based virtual mental health assistant that provides mental health tips and information to users, automating initial engagement and information delivery for mental health content.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Atados
Strategic tierMinorTypeGTM or Marketing Partner
Description

Medley partnered with Atados, a volunteer platform, to connect NGOs with people who want to volunteer. The partnership aims to promote social causes and women's support initiatives.

medley.com.br
2Brazilian Olympic Committee (COB - Comitê Olímpico do Brasil)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Medley is an official sponsor of the Brazilian Olympic Committee. The partnership includes Olympic branding and athlete health support initiatives.

medley.com.br
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1EMS Group
TypeDirect peer
Description

Brazil's largest generics manufacturer with ~23% market share; in 2026 signed a definitive agreement to acquire 100% of Medley from Sanofi, making it the most directly comparable peer across product, customer base, and channel.

TypeDirect peer
Description

Privately-held Brazilian pharmaceutical company with a significant generics and branded-generics portfolio distributed through pharmacy retail, overlapping directly with Medley's therapeutic categories and GTM motion.

TypeDirect peer
Description

One of Brazil's largest pharma companies (formerly Hypermarcas), competing in generics, OTC, and consumer health; was a competing bidder for Medley in 2026 and shares the same pharmacy-channel distribution model.

TypeDirect peer
Description

Brazilian pharma manufacturer across prescription, generics, and OTC categories; competing bidder for Medley in 2026 and a direct competitor for the same pharmacy and retail customers.

TypeDirect peer
Description

Brazilian pharma company with prescription and OTC generics lines sold through retail pharmacy; also a competing bidder for Medley in 2026, indicating direct overlap in business model and customer base.

TypeBroad incumbent
Description

Medley's former parent (2009-2026) and a global pharmaceutical major with a broader branded-prescription and vaccines focus in Brazil; comparable as a manufacturer in the same country, but not specialized in generics.

TypeBroad incumbent
Description

Global pharma major with a generics arm (Sandoz) operating in Brazil; broader portfolio than Medley but a relevant incumbent competing in the same generic-pharmacy channel.

TypeBroad incumbent
Description

World's largest generic-drug manufacturer with operations in Brazil; comparable in product type (oral solids, generics) but at a different scale and geographic footprint.

TypeBroad incumbent
Description

Global pharma major with established OTC and consumer-health presence in Brazilian pharmacy retail; broader portfolio than Medley, overlapping in OTC/analgesics and respiratory categories.

TypeBroad incumbent
Description

Global pharmaceutical company with branded prescription and consumer-health operations in Brazil; comparable as a manufacturer selling through the same pharmacy channels but not focused on generics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medley

Generic Pharmaceuticalsmedley.com.br

Medley Farmacêutica is a Brazilian generic pharmaceutical manufacturer founded in 1996, producing tablets, capsules, liquids, and creams across 8+ therapeutic categories from its ~1,800-employee Campinas facility and serving Brazilian pharmacy retailers and patients with an 8% generics market share.

What Medley does

Medley Farmacêutica Ltda. is a Brazilian generic pharmaceutical manufacturer founded in 1996 and headquartered in Campinas, São Paulo. It produces tablets, capsules, liquids, ointments, creams, and suspensions across more than eight therapeutic categories — anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants/anti-allergic, gynecological/urological, and anti-inflammatory/analgesic/antipyretic — and holds an estimated 8% share of Brazil's generics segment, where generics account for roughly 40% of the country's pharmaceutical market. Manufacturing is concentrated at a single ~1,800-employee Campinas production site on R. Macedo Costa, 55; the company operates under ANVISA regulatory oversight and maintains LGPD-compliant data practices.

The company's business model is sales-led distribution of generic medicines through Brazilian pharmacy retail chains, independent drugstores, and online pharmacy partners such as consultaremedios.com.br, targeting both end consumers and pharmacy/distributor buyers. Revenue derives from one-time unit sales across a portfolio of 100+ generic SKUs, with no disclosed subscription or licensing model. Medley complements its core generics franchise with branded OTC extensions (Termomed Ibup, Medalgesico, Medmulher), a nutraceutical product (Biscal D, launched in India in December 2025), and a digital mental-health engagement layer via Cássia on WhatsApp.

From 2009 until March 2026, Medley operated as a wholly-owned subsidiary of Sanofi. In March 2026, Sanofi signed a definitive agreement to sell 100% of Medley to Brazilian pharmaceutical group EMS for approximately BRL 3.2–3.6 billion (~US$660–670 million), at roughly 16x EBITDA, pending approval from Brazil's antitrust authority CADE. The deal would consolidate Medley with EMS's 23% generics share into a combined 31% market-leading position, with competing bids reported from Sun Pharma, Hypera Pharma, Biolab, and Aché.

Medley firmographics

Firmographics
Name
Medley
Legal name
MEDLEY FARMACÊUTICA LTDA.
Website
https://medley.com.br
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Medley Farmacêutica is a Brazilian generic pharmaceutical manufacturer founded in 1996, producing tablets, capsules, liquids, and creams across 8+ therapeutic categories from its ~1,800-employee Campinas facility and serving Brazilian pharmacy retailers and patients with an 8% generics market share.
Ownership category
akta.pro rank

Medley industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Generic Hospital & Institutional Products (HLAIABAL)
akta.pro secondary industry
Women’s Health (OTC Gynecologic) (HLAIADAJ)

Keywords

  • Generic pharmaceuticals
  • Generic medications
  • OTC medicines
  • Pharmaceutical manufacturing
  • Generic drugs Brazil

Where Medley is headquartered

Location

Headquarters

HQ city
Campinas
HQ country
Brazil
HQ region
Latin America

Offices2 records

Markets served

Medley business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic pharmaceutical products: Medley generates revenue through the manufacture and sale of generic pharmaceutical products across multiple therapeutic categories including anti-infectives, cardiovascular, central nervous system, dermatologicals, gastrointestinal, and other medications. The company operates in Brazil's generics segment where generic medicines account for approximately 40% of the pharmaceutical market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Medley product offering

Product offering

Core offering

Medley manufactures and supplies a comprehensive portfolio of generic pharmaceutical products in multiple dosage forms (tablets, capsules, liquids, ointments, creams, and suspensions) spanning therapeutic categories including anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants, and gynecological/urological medications. The company also markets over-the-counter (OTC) brands such as Termomed Ibup, Medalgesico, and Medmulher, and operates the Cássia WhatsApp-based virtual mental health assistant.

Product overview

Medley is a leading Brazilian pharmaceutical company specializing in generic medications. The company produces a comprehensive portfolio of generic drugs including tablets, capsules, liquids, ointments, creams, and suspensions across multiple therapeutic categories: anti-infectives, anti-inflammatory/analgesic/antipyretic, cardiovascular, dermatological, gastrointestinal, expectorants/anti-allergic, gynecological/urological, and central nervous system medications. Medley also offers over-the-counter products including Termomed Ibup (fever relief), Medalgesico (pain and fever relief), and Medmulher (women's health). Additionally, the company offers digital health services through Cássia, a WhatsApp-based virtual mental health assistant. Founded in 1996 and acquired by Sanofi in 2009, Medley was subsequently acquired by EMS Group in 2026 for approximately BRL 3.2-3.6 billion (~$660-670 million).

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Medications Portfolio Comprehensive portfolio of generic medications including tablets, capsules, liquids, ointments, creams, and suspensions spanning therapeutic categories such as anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants, and gynecological/urological medications for the Brazilian population.
  • Termomed Ibup Over-the-counter analgesic product providing fever relief for the whole family.
  • Medalgesico Over-the-counter pain relief and fever medication for the whole family.
  • Medmulher Over-the-counter medication line focused on women's health.
  • Biscal D A fortified biscuit product containing Calcium and Vitamin D3 aimed at addressing nutritional deficiencies in pregnant women, lactating mothers, and postmenopausal women, launched in the Indian nutraceutical market.
  • Cássia WhatsApp-based virtual mental health assistant that provides mental health tips and information to users, automating initial engagement and information delivery for mental health content.

Quantifiable outcome

  • Brazil's generics market represents approximately 40% of the total pharmaceutical market

Companies that use Medley

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Medley technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Medley partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • AtadosminorGTM or Marketing PartnerMedley partnered with Atados, a volunteer platform, to connect NGOs with people who want to volunteer. The partnership aims to promote social causes and women's support initiatives.
  • Brazilian Olympic Committee (COB - Comitê Olímpico do Brasil)coreGTM or Marketing PartnerMedley is an official sponsor of the Brazilian Olympic Committee. The partnership includes Olympic branding and athlete health support initiatives.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Medley competitors and assessment

Company assessment

Direct peers

  • EMS Group: Brazil's largest generics manufacturer with ~23% market share; in 2026 signed a definitive agreement to acquire 100% of Medley from Sanofi, making it the most directly comparable peer across product, customer base, and channel.
  • Eurofarma Laboratórios: Privately-held Brazilian pharmaceutical company with a significant generics and branded-generics portfolio distributed through pharmacy retail, overlapping directly with Medley's therapeutic categories and GTM motion.
  • Hypera Pharma: One of Brazil's largest pharma companies (formerly Hypermarcas), competing in generics, OTC, and consumer health; was a competing bidder for Medley in 2026 and shares the same pharmacy-channel distribution model.
  • Aché Laboratórios Farmacêuticos: Brazilian pharma manufacturer across prescription, generics, and OTC categories; competing bidder for Medley in 2026 and a direct competitor for the same pharmacy and retail customers.
  • Biolab Farmacêutica: Brazilian pharma company with prescription and OTC generics lines sold through retail pharmacy; also a competing bidder for Medley in 2026, indicating direct overlap in business model and customer base.

Broad incumbents

  • Sanofi: Medley's former parent (2009-2026) and a global pharmaceutical major with a broader branded-prescription and vaccines focus in Brazil; comparable as a manufacturer in the same country, but not specialized in generics.
  • Novartis (Sandoz): Global pharma major with a generics arm (Sandoz) operating in Brazil; broader portfolio than Medley but a relevant incumbent competing in the same generic-pharmacy channel.
  • Teva Pharmaceutical Industries: World's largest generic-drug manufacturer with operations in Brazil; comparable in product type (oral solids, generics) but at a different scale and geographic footprint.
  • GSK (GlaxoSmithKline Brasil): Global pharma major with established OTC and consumer-health presence in Brazilian pharmacy retail; broader portfolio than Medley, overlapping in OTC/analgesics and respiratory categories.
  • Pfizer Brasil: Global pharmaceutical company with branded prescription and consumer-health operations in Brazil; comparable as a manufacturer selling through the same pharmacy channels but not focused on generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Medley social profiles

Digital presence

Medley compliance and trust

Trust signal

Compliance1 record

Medley financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medley leadership team

Management profile

Number of profiles

Medley funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medley M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medley

What does Medley do?

Medley manufactures and supplies a comprehensive portfolio of generic pharmaceutical products in multiple dosage forms (tablets, capsules, liquids, ointments, creams, and suspensions) spanning therapeutic categories including anti-infectives, cardiovascular, central nervous system, dermatological, gastrointestinal, expectorants, and gynecological/urological medications. The company also markets over-the-counter (OTC) brands such as Termomed Ibup, Medalgesico, and Medmulher, and operates the Cássia WhatsApp-based virtual mental health assistant.

Is Medley a public or private company?

Medley is a private company. It is classified as corporate owned and is currently operating.

When was Medley founded?

Medley was founded in 1996. It employs 501 to 1,000 people.

Where is Medley based?

Medley is headquartered in Campinas, Brazil, in the Latin America region.

How does Medley make money?

One revenue line is on record: generic pharmaceutical products.

Who are Medley's main competitors?

Direct peers on record are EMS Group, Eurofarma Laboratórios, Hypera Pharma, Aché Laboratórios Farmacêuticos and Biolab Farmacêutica. Broad incumbents are Sanofi, Novartis (Sandoz), Teva Pharmaceutical Industries, GSK (GlaxoSmithKline Brasil) and Pfizer Brasil.

Does Medley have an API?

No public API is recorded for Medley.

What industry is Medley in?

Medley's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIADAJ, Women’s Health (OTC Gynecologic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FolhaCade vê compra da Medley pela EMS como 'complexa', frustra empresas e vai aprofundar análiseCade declared the Medley-EMS merger complex, ordering further analysis of the R$3.2B deal. The agency will assess competition in ovulation stimulants and migraine drugs, with a final decision expected in October.NeofeedO que Cimed e concorrentes disseram ao Cade sobre a aquisição da Medley pela EMSCADE, Brazil's antitrust authority, heard 65 pharmaceutical companies regarding EMS's proposed $600 million acquisition of Medley from French company Sanofi. Cimed emerged as the most vocal critic, arguing the deal would increase EMS's bargaining power, reduce competition, and negatively impact prices and services for consumers in the Brazilian generics market. Other companies like União Química and Althaia shared similar concerns about market concentration, while Pfizer countered that the acquisition would benefit consumers, and EMS maintains that product overlap will not create excessive concentration, with CADE's final decision expected by April 2027.MarketScreenerBrazil’s EMS buys MedleyEMS Group has agreed to acquire 100% of Brazilian generics producer Medley from Sanofi for approximately BRL 3.6 billion ($670 million), concluding a bidding process that also drew proposals from Sun Pharma, Hypera Pharma, Biolab Farmacêutica, and Aché Laboratórios Farmacêuticos. Medley, founded in 1996 and acquired by Sanofi in 2009, operates a manufacturing site in Campinas employing about 1,800 people and produces tablets, capsules, liquids, ointments, creams, and suspensions. The deal, which requires approval from Brazil's Administrative Council for Economic Defense (CADE) and other regulatory bodies, will expand EMS's medicines portfolio and strengthen its position in Brazil's generics segment, where generic medicines account for about 40% of the pharmaceutical market.EmsGrupo EMS e Sanofi assinam acordo estratégico de venda para apoiar a próxima fase de crescimento da Medley no mercado de genéricos do Brasil - EMSGrupo EMS, a major Brazilian pharmaceutical conglomerate, signed a definitive agreement to acquire 100% of Medley, one of Brazil's leading generic drug brands, from Sanofi for an undisclosed amount. The transaction, subject to approval by Brazil's antitrust authority CADE, aims to combine Medley's brand strength in Brazil's generic market with EMS's industrial scale and manufacturing capabilities. Sanofi will use the divestiture to focus its Brazil operations on innovative biopharmaceuticals and vaccines, while EMS expects the acquisition to expand its offerings and access in the generic segment.pegnEMS outbids competitors with R$3.2bn deal for MedleyBrazilian drugmaker EMS has finalized the acquisition of Medley, a generics company owned by French pharmaceutical giant Sanofi, for R$3.2 billion (approximately 16x EBITDA). The deal outbid competing proposals from Sun Pharma, Hypera Pharma, Biolab Farmacêutica, and Aché Laboratórios Farmacêuticos, with India-based Sun Pharma having been considered the favorite before EMS presented a higher offer. The acquisition strengthens EMS's position as the leading generics drug manufacturer in Brazil, with the transaction expected to be announced publicly later that Friday.Brazil JournalEMS compra a Medley e consolida liderança em genéricosEMS, a Brazilian pharmaceutical company controlled by Grupo NC under CEO Carlos Sanchez, has acquired the generic drug laboratory Medley from Sanofi for approximately US$ 660 million (R$ 3.5 billion), consolidating its position as the leader in Brazil's generics market with 31% combined market share. The deal still requires approval from CADE, Brazil's antitrust authority, and represents both a defensive move to block low-cost international players like India's Sun Pharma and a scale play by combining EMS's 23% share with Medley's 8%. Sources say Sanchez paid a premium over competing offers from Hypera, Aché, Biolab, Vinci Compass, and Sun to ensure he would not face a consolidated rival in the generics segment.Express PharmaMedley launches Biscal D –Calcium and Vitamin D3 fortified biscuitMedley announced the launch of Biscal D, a fortified biscuit product containing Calcium and Vitamin D3 aimed at addressing nutritional deficiencies in India. The product targets pregnant women, lactating mothers, and postmenopausal women, and is positioned to tap into the growing Indian nutraceutical market.